Assoc. Professorin Priv. Doz. Dr. med. & Dr. phil.
JOLANTA SILLER-MATULA

Wissenschaftliche Publikationen
0
Herzkatheter Untersuchungen/Eingriffe
0
Eingeladene Vorträge
0
Preise und Auszeichnungen
0
Zitate
0
Hirsch index
0
i10-index
0
  • Fachärztin für Innere Medizin und Kardiologie auf der Abteilung für Kardiologie, Medizinische Universität Wien, AKH
  • Schwerpunkt: interventionelle Kardiologie
  • Fokus auf antithrombotische Therapien und personalisierte Behandlung von Herzerkrankungen

Nach Studium von Humanmedizin und breitgefächerter Ausbildung 2007-2018 an der Medizinischen Universität Wien und mehrjähriger Tätigkeit in unterschiedlichen Teilgebieten der Inneren Medizin und Kardiologie verfüge ich über ein hohes Maß an fachspezifischem Wissen mit Schwerpunkt in interventioneller Kardiologie. Darüber hinaus, gehören zu meinen klinischen Schwerpunkten die Echokardiographie, nicht-invasive Rhythmologie sowie Management struktureller Herzerkrankungen (Herzvitien, diastolische und systolische Herzinsuffizienz). Ich bin in meiner klinischen Tätigkeit von wissenschaftlicher Evidenz und ethischen Grundsätzen geleitet. Im Rahmen meiner klinischen aber auch wissenschaftlichen Tätigkeit befasse ich mich intensiv mit Zukunftsfragen der Kardiologie. Hier sind aus meiner Sicht vor allem die Fortschritte in der Präzisionsmedizin für die Verbesserung des netto klinischen Benefits des Patienten sowie die geschlechtsspezifische Behandlung von Herzerkrankungen von Relevanz. Als besondere Anerkennung für meine klinische sowie wissenschaftliche Arbeit sehe ich die Nominierung als Board Mitglied der Europäischen Gesellschaft für Interventionelle Kardiologie (EAPCI) sowie die Zuerkennung einer Exzellenz-Auszeichnung in der interventionellen Kardiologie – des TCT Linnemeier Spirit of Interventional Cardiology Awards (Orlando, USA, 2021).

  • Internationale Anerkennung als Expertin für Interventionelle Kardiologie und Antithrombotische Therapie
  • Überdurchschnittliche wissenschaftliche Performanz mit über 200 Publikationen
  • Volksgesundheitliche und klinische Relevanz der Forschungsergebnisse

Als Doktorandin führte ich Studien an Gerrinnung unter Aufsicht von Prof. Bernd Jilma (Abteilung für Klinische Pharmakologie, MUW). Ein Abschluss der Doktoratstudiums (PhD) folgte 2011 und Venia legendi (Habilitation) für Innere Medizin in 2012. Danach erweiterte ich mein Forschungbereich auf koronare und Klappen- Thrombose und die personalisierte antithrombotische Therapie sowie die Therapie von Herzerkrankungen in Frauen. Meine Veröffentlichungen haben zu einer Debatte in der Kardiologie über die Wirksamkeit und Sicherheit der konventionellen Thrombozytenaggregationshemmung beigetragen, und wurden in den europäischen und amerikanischen Richtlinien für Kardiologie zitiert. In meiner klinisch orientierten Forschung konzentrierte ich mich auf die optimale Kombination und Dauer der antithrombotischen Therapie nach koronaren Interventionen und transkatheter-Klappeneingriffen.

Als Leiterin einer internationalen Forschungsgruppe (I-COMET) erforsche ich mit meinem Team die kardiometabolischen Effekte von neuen Medikamentengruppen.

In englicher Sprache
  1. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I, Geisler T, Hinterbuchner L, Ibanez B, Lenarczyk R, Mansmann UR, McGreavy P, Mueller C, Muneretto C, Niessner A, Potpara TS, Ristic A, Sade LE, Schirmer H, Schupke S, Sillesen H, Skulstad H, Torracca L, Tutarel O, Van Der Meer P, Wojakowski W, Zacharowski K, Group ESCSD, Knuuti J, Kristensen SD, Aboyans V, Ahrens I, Antoniou S, Asteggiano R, Atar D, Baumbach A, Baumgartner H, Bohm M, Borger MA, Bueno H, Celutkiene J, Chieffo A, Cikes M, Darius H, Delgado V, Devereaux PJ, Duncker D, Falk V, Fauchier L, Habib G, Hasdai D, Huber K, Iung B, Jaarsma T, Konradi A, Koskinas KC, Kotecha D, Landmesser U, Lewis BS, Linhart A, Lochen ML, Maeng M, Manzo-Silberman S, Mindham R, Neubeck L, Nielsen JC, Petersen SE, Prescott E, Rakisheva A, Saraste A, Sibbing D, SILLER-MATULA J, Sitges M, Stankovic I, Storey RF, Ten Berg J, Thielmann M and Touyz RM. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022, online first.
  2. von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, Alber H, Berger R, Lichtenauer M, Saely CH, Moertl D, Auersperg P, Reiter C, Rieder T, SILLER-MATULA JM, Gager GM, Hasun M, Weidinger F, Pieber TR, Zechner PM, Herrmann M, Zirlik A, Holman RR, Oulhaj A and Sourij H. Empagliflozin in acute Myocardial Infarction: the EMMY trial. Eur Heart J. 2022.
  3. Fedorowski A, SILLER-MATULA JM and Patti G. Thrombosis and fibrinolysis in atherosclerotic cardiovascular disease: it takes two to tango. Eur Heart J. 2022;43:982-984.
  4. Gager GM, Eyileten C, Postula M, Gasecka A, Jarosz-Popek J, Gelbenegger G, Jilma B, Lang I and SILLER-MATULA J. Association Between the Expression of MicroRNA-125b and Survival in Patients With Acute Coronary Syndrome and Coronary Multivessel Disease. Front Cardiovasc Med. 2022;9:948006.
  5. Wicik Z, Nowak A, Jarosz-Popek J, Wolska M, Eyileten C, SILLER-MATULA JM, von Lewinski D, Sourij H, Filipiak KJ and Postula M. Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis. Front Pharmacol. 2022;13:901340.
  6. Wicik Z, Czajka P, Eyileten C, Fitas A, Wolska M, Jakubik D, von Lewinski D, Sourij H, SILLER-MATULA JM and Postula M. The role of miRNAs in regulation of platelet activity and related diseases – a bioinformatic analysis. Platelets. 2022;33:1052-1064.
  7. Weight N, Moledina S, Zoccai GB, Zaman S, Smith T, SILLER-MATULA J, Dafaalla M, Rashid M, Nolan J and Mamas MA. Impact of pre-existing vascular disease on clinical outcomes in patients with non-ST-segment myocardial infarction: a nationwide cohort study. Eur Heart J Qual Care Clin Outcomes. 2022.
  8. Sandner S, Angleitner P, Netuschill C, Stasek S, Manville E, SILLER-MATULA J, Laufer G and Zimpfer D. External stenting of saphenous vein grafts for coronary artery bypass: a single-center analysis of clinical outcomes. J Cardiovasc Surg (Torino). 2022;63:187-194.
  9. Latif A, Ahsan MJ, Lateef N, Aurit S, Mirza MM, SILLER-MATULA JM, Mamas MA, Parikh M, Brilakis ES, Abbott JD, Bhatt DL and Velagapudi P. Impact of sex on outcomes of percutaneous coronary intervention for chronic total occlusion: A meta-analysis. Catheter Cardiovasc Interv. 2022;99:254-262.
  10. Kubica J, Adamski P, Ladny JR, Kazmierczak J, Fabiszak T, Filipiak KJ, Gajda R, Gasior M, Gasior Z, Gil R, Goracy J, Grajek S, Gromadzinski L, Gruchala M, Grzesk G, Hoffman P, Jaguszewski MJ, Janion M, Jankowski P, Kalarus Z, Kasprzak JD, Kleinrok A, Kochman W, Kubica A, Kuliczkowski W, Legutko J, Lesiak M, Nadolny K, Navarese EP, Niezgoda P, Ostrowska M, Paciorek P, SILLER-MATULA J, Szarpak L, Timler D, Witkowski A, Wojakowski W, Wysokinski A and Zielinska M. Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022. Cardiol J. 2022;29:540-552.
  11. Kubica J, Adamski P, Gorog DA, Kubica A, Jilma B, Budaj A, SILLER-MATULA JM, Gurbel PA, Alexopoulos D, Badariene J, Dabrowski P, Dudek D, Giannitsis E, Horszczaruk G, Jaguszewski MJ, James S, Jeong YH, Kryjak M, Niezgoda P, Ostrowska M, Patti G, Romanek J, Di Somma S, Specchia G, Tantry U, Gasior M, Tycinska A, Wojakowski W, Buszko K, Gil R, Gruchala M, Kasprzak J, Kleinrok A, Legutko J, Lesiak M and Navarese EP. Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. Cardiol J. 2022;29:148-153.
  12. Jorda A, SILLER-MATULA JM, Zeitlinger M, Jilma B and Gelbenegger G. Anticoagulant Treatment Regimens in Patients With Covid-19: A Meta-Analysis. Clin Pharmacol Ther. 2022;111:614-623.
  13. Jorda A, Kussmann M, Kolenchery N, SILLER-MATULA JM, Zeitlinger M, Jilma B and Gelbenegger G. Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis. Front Immunol. 2022;13:817829.
  14. Jaiswal V, Ang SP, Chia JE, Abdelazem EM, Jaiswal A, Biswas M, Gimelli A, Parwani P, SILLER-MATULA JM and Mamas MA. Echocardiographic predictors of presence of cardiac amyloidosis in aortic stenosis. Eur Heart J Cardiovasc Imaging. 2022.
  15. Gelbenegger G, Grafeneder J, Gager GM, SILLER-MATULA JM, Schwameis M, Jilma B and Schoergenhofer C. Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial. Thromb J. 2022;20:19.
  16. Eyileten C, Wicik Z, Simoes SN, Martins-Jr DC, Klos K, Wlodarczyk W, Assinger A, Soldacki D, Chcialowski A, SILLER-MATULA JM and Postula M. Thrombosis-related circulating miR-16-5p is associated with disease severity in patients hospitalised for COVID-19. RNA Biol. 2022;19:963-979.
  17. Eyileten C, Wicik Z, Keshwani D, Aziz F, Aberer F, Pferschy PN, Tripolt NJ, Sourij C, Prietl B, Pruller F, von Lewinski D, De Rosa S, SILLER-MATULA JM, Postula M and Sourij H. Alteration of circulating platelet-related and diabetes-related microRNAs in individuals with type 2 diabetes mellitus: a stepwise hypoglycaemic clamp study. Cardiovasc Diabetol. 2022;21:79.
  18. Eyileten C, Gasecka A, Nowak A, Jarosz-Popek J, Wolska M, Dizdarevic AM, Lang IM, Postula M, Ufnal M and SILLER-MATULA JM. High concentration of symmetric dimethylarginine is associated with low platelet reactivity and increased bleeding risk in patients with acute coronary syndrome. Thromb Res. 2022;213:195-202.
  19. Doolub G, Kobo O, Mohamed MO, Ullah W, Alraies MC, Velagapudi P, SILLER-MATULA JM, Roguin A, Bagur R and Mamas MA. Outcomes of Percutaneous Coronary Intervention in Patients With Acquired Immunosuppression. Am J Cardiol. 2022;171:40-48.
  20. Dona C, Koschutnik M, Nitsche C, Winter MP, Seidl V, SILLER-MATULA J, Mach M, Andreas M, Bartko P, Kammerlander AA, Goliasch G, Lang I, Hengstenberg C and Mascherbauer J. Cerebral Protection in TAVR-Can We Do Without? A Real-World All-Comer Intention-to-Treat Study-Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality. J Pers Med. 2022;12.
  21. Bogyi M and SILLER-MATULA JM. Reply: Prosthesis Type-Associated Risk of Subclinical Leaflet Thrombosis. JACC Cardiovasc Interv. 2022;15:676-677.
  22. Aziz F, Reisinger AC, Aberer F, Sourij C, Tripolt N, SILLER-MATULA JM, von-Lewinski D, Eller P, Kaser S, Sourij H and On Behalf Of The Covid-In Diabetes In Austria Study G. Simplified Acute Physiology Score 3 Performance in Austrian COVID-19 Patients Admitted to Intensive Care Units with and without Diabetes. Viruses. 2022;14.
  23. Winter MP, Bartko PE, Krickl A, Gatterer C, Dona C, Nitsche C, Koschutnik M, Spinka G, SILLER-MATULA JM, Lang IM, Mascherbauer J, Hengstenberg C and Goliasch G. Adaptive development of concomitant secondary mitral and tricuspid regurgitation after transcatheter aortic valve replacement. Eur Heart J Cardiovasc Imaging. 2021;22:1045-1053.
  24. Traby L, Kollars M, Kaider A, SILLER-MATULA JM, Steinbrecher O, Wolzt M, Kyrle PA and Eichinger S. Differential Effects of Clopidogrel With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers. Clin Pharmacol Ther. 2021;109:1546-1554.
  25. SILLER-MATULA JM and Shah B. Sex Differences in Treatment and Outcomes in Non-ST-Elevation Acute Coronary Syndrome: A Persistent Disparity. Circ Cardiovasc Interv. 2021;14:e010329.
  26. Rohla M, Pecen L, Cemin R, Patti G, SILLER-MATULA JM, Schnabel RB, Huber K, Kirchhof P and De Caterina R. Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. Circ Cardiovasc Qual Outcomes. 2021;14:e006852.
  27. Renda G, Pecen L, Patti G, Ricci F, Kotecha D, SILLER-MATULA JM, Schnabel RB, Wachter R, Sellal JM, Rohla M, Lucerna M, Huber K, Verheugt FWA, Zamorano JL, Bruggenjurgen B, Darius H, Duytschaever M, Le Heuzey JY, Schilling RJ, Kirchhof P and De Caterina R. Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. Intern Emerg Med. 2021;16:591-599.
  28. Pordzik J, Eyileten-Postula C, Jakubik D, Czajka P, Nowak A, De Rosa S, Gasecka A, Cieslicka-Kaplon A, Sulikowski P, Filipiak KJ, Mirowska-Guzel D, SILLER-MATULA JM and Postula M. MiR-126 Is an Independent Predictor of Long-Term All-Cause Mortality in Patients with Type 2 Diabetes Mellitus. J Clin Med. 2021;10.
  29. Perek B, Rzymski P, Komosa A, Olasinska-Wisniewska A, Puslecki M, Jemielity M, Lesiak M, Aboul-Hassan SS, Stankowski T, Xia Z, Stelmark K, SILLER-MATULA J and Poniedzialek B. Mean platelet volume-to-platelet count ratio after elective cardiac surgical procedures is superior in reflecting platelets metabolic hyperactivity compared to other routine morphological platelet indices: A preliminary report. Cardiol J. 2021.
  30. Nitsche C, Kammerlander AA, Koschutnik M, Sinnhuber L, Forutan N, Eidenberger A, Dona C, Schartmueller F, Dannenberg V, Winter MP, SILLER-MATULA J, Anvari-Pirsch A, Goliasch G, Hengstenberg C and Mascherbauer J. Fluid overload in patients undergoing TAVR: what we can learn from the nephrologists. ESC Heart Fail. 2021;8:1408-1416.
  31. Nitsche C, Kammerlander AA, Koschutnik M, Dona C, Aschauer S, Sinnhuber L, Eidenberger A, Forutan N, Schartmueller F, Andreas M, Beitzke D, Bergler-Klein J, Bartko PE, SILLER-MATULA J, Winter MP, Anvari-Pirsch A, Goliasch G, Hengstenberg C and Mascherbauer J. Volume Status Impacts CMR-Extracellular Volume Measurements and Outcome in AS Undergoing TAVR. JACC Cardiovasc Imaging. 2021;14:516-518.
  32. Latif A, Ahsan MJ, Mirza MM, Aurit S, SILLER-MATULA J, Mamas MA, Parikh M, Brilakis ES, Abbott JD, Bhatt DL and Velagapudi P. Meta-Analysis of Transradial Versus Transfemoral Access for Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease. Am J Cardiol. 2021;157:8-14.
  33. Kubica J, Kubica A, Grzelakowska K, Stolarek W, Grabczewska Z, Michalski P, Niezgoda P, Bartus S, Budaj A, Dabrowski M, Drozdz J, Gellert R, Jaguszewski M, Jankowski P, Legutko J, Lesiak M, Leszek P, Malyszko J, Mitkowski P, Nessler J, Pawlaczyk K, SILLER-MATULA J, Stompor T, Wolnik B and Navarese EP. Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients. Cardiol J. 2021.
  34. Kubica J, Adamski P, Niezgoda P, Kubica A, Podhajski P, Baranska M, Uminska JM, Pietrzykowski L, Ostrowska M, SILLER-MATULA JM, Badariene J, Bartus S, Budaj A, Dobrzycki S, Fidor L, Gasior M, Gessek J, Gierlotka M, Gil R, Goracy J, Grzelakowski P, Hajdukiewicz T, Jaguszewski M, Janion M, Kasprzak J, Kern A, Klecha A, Kleinrok A, Kochman W, Krakowiak B, Legutko J, Lesiak M, Nosal M, Piotrowski G, Przybylski A, Roleder T, Skonieczny G, Sobieszek G, Tycinska A, Wojciechowski D, Wojakowski W, Wojcik J, Zielinska M, Zurakowski A, Specchia G, Gorog DA and Navarese EP. A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiol J. 2021;28:607-614.
  35. Koschutnik M, Dannenberg V, Nitsche C, Dona C, SILLER-MATULA JM, Winter MP, Andreas M, Zafar A, Bartko PE, Beitzke D, Loewe C, Aschauer S, Anvari-Pirsch A, Goliasch G, Hengstenberg C, Kammerlander AA and Mascherbauer J. Right ventricular function and outcome in patients undergoing transcatheter aortic valve replacement. Eur Heart J Cardiovasc Imaging. 2021;22:1295-1303.
  36. Komosa A, Perek B, Rzymski P, Poniedzialek B, Grygier M, Siniawski A, Szabatowska K, SILLER-MATULA J, Jemielity M, Misterski M and Lesiak M. Platelet function in patients undergoing surgical and transcatheter aortic valve replacement: a comparative study. Kardiol Pol. 2021;79:554-561.
  37. Jasiewicz M, Siedlaczek M, Kasprzak M, Gorog DA, Jilma B, SILLER-MATULA J, Obonska K, Dobosiewicz R, Pstragowski K and Kubica J. Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials? Cardiol J. 2021.
  38. Jakubik D, Fitas A, Eyileten C, Jarosz-Popek J, Nowak A, Czajka P, Wicik Z, Sourij H, SILLER-MATULA JM, De Rosa S and Postula M. MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics. Cardiovasc Diabetol. 2021;20:55.
  39. Hofer F, Perkmann T, Gager G, Winter MP, Niessner A, Hengstenberg C and SILLER-MATULA JM. Comparison of high-sensitivity C-reactive protein vs. C-reactive protein for diagnostic accuracy and prediction of mortality in patients with acute myocardial infarction. Ann Clin Biochem. 2021;58:342-349.
  40. Grajek S, Kaluzna-Oleksy M, SILLER-MATULA JM, Grajek M and Michalak M. Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Myocardial Infarction in Patients with Atrial Fibrillation with or without Percutaneous Coronary Interventions: A Meta-Analysis. J Pers Med. 2021;11.
  41. Gorog DA, Price S, Sibbing D, Baumbach A, Capodanno D, Gigante B, Halvorsen S, Huber K, Lettino M, Leonardi S, Morais J, Rubboli A, SILLER-MATULA JM, Storey RF, Vranckx P and Rocca B. Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J Cardiovasc Pharmacother. 2021;7:125-140.
  42. Gelbenegger G, Schoergenhofer C, Jilma B, Gager GM, Dizdarevic AM, Mamas MA, Parapid B, Velagapudi P and SILLER-MATULA JM. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. Clin Pharmacol Ther. 2021;110:424-431.
  43. Gelbenegger G, Erari-Canyurt U, Grafeneder J, Jilma B, Lesiak M, Komosa A, de Caterina R, Postula M and SILLER-MATULA JM. Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: a meta-analysis. Vascul Pharmacol. 2021;138:106858.
  44. Gajanan G, Brilakis ES, SILLER-MATULA JM, Zolty RL and Velagapudi P. The Intra-Aortic Balloon Pump. J Vis Exp. 2021.
  45. Gager GM, von Lewinski D, Sourij H, Jilma B, Eyileten C, Filipiak K, Hulsmann M, Kubica J, Postula M and SILLER-MATULA JM. Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. Biomed Pharmacother. 2021;143:112169.
  46. Gager GM, Gelbenegger G, Jilma B, von Lewinski D, Sourij H, Eyileten C, Filipiak K, Postula M and SILLER-MATULA JM. Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis. Front Cardiovasc Med. 2021;8:691907.
  47. Eyileten C, Jarosz-Popek J, Jakubik D, Gasecka A, Wolska M, Ufnal M, Postula M, Toma A, Lang IM and SILLER-MATULA JM. Plasma Trimethylamine-N-Oxide Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. Front Cardiovasc Med. 2021;8:728724.
  48. Czajka P, Fitas A, Jakubik D, Eyileten C, Gasecka A, Wicik Z, SILLER-MATULA JM, Filipiak KJ and Postula M. MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review. Front Physiol. 2021;12:652579.
  49. Borrelli N, Brida M, Cader A, Sabatino J, Czerwinska-Jelonkiewicz K, Shchendrygina A, Wood A, Allouche E, Avesani M, Gok G, Marchenko O, Calvieri C, Baritussio A, Ilardi F, Caglar N, Moscatelli S, Kotlar I, Trepa M, Rubini MG, Chrysohoou C, Jovovic L, Prokselj K, Simkova I, Babazade N, SILLER-MATULA J, Chikhi F, Kovacevic-Preradovic T, Srbinovska E, Johnson V, Farrero M, Moharem-Elgamal S and Gimelli A. Women leaders in Cardiology. Contemporary profile of the WHO European region. Eur Heart J Open. 2021;1:oeab008.
  50. Bogyi M, Schernthaner RE, Loewe C, Gager GM, Dizdarevic AM, Kronberger C, Postula M, Legutko J, Velagapudi P, Hengstenberg C and SILLER-MATULA JM. Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement: A Meta-Analysis. JACC Cardiovasc Interv. 2021;14:2643-2656.
  51. Biesinger BS, Gasecka A, Perkmann T, Wojta J, Lesiak M, Grygier M, Eyileten C, Postula M, Filipiak KJ, Toma A, Hengstenberg C and SILLER-MATULA JM. Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS. Platelets. 2021;32:498-506.
  52. Aziz F, Aberer F, Brauer A, Ciardi C, Clodi M, Fasching P, Karolyi M, Kautzky-Willer A, Klammer C, Malle O, Pawelka E, Pieber T, Peric S, Ress C, Schranz M, Sourij C, Stechemesser L, Stingl H, Stocher H, Stulnig T, Tripolt N, Wagner M, Wolf P, Zitterl A, Reisinger AC, SILLER-MATULA J, Hummer M, Moser O, von-Lewinski D, Eller P, Kaser S and Sourij H. COVID-19 In-Hospital Mortality in People with Diabetes Is Driven by Comorbidities and Age-Propensity Score-Matched Analysis of Austrian National Public Health Institute Data. Viruses. 2021;13.
  53. Zareba L, Fitas A, Wolska M, Junger E, Eyileten C, Wicik Z, De Rosa S, SILLER-MATULA JM and Postula M. MicroRNAs and Long Noncoding RNAs in Coronary Artery Disease: New and Potential Therapeutic Targets. Cardiol Clin. 2020;38:601-617.
  54. Winter MP, Goliasch G, Bartko P, SILLER-MATULA J, Ayoub M, Aschauer S, Distelmaier K, Gebhard C, Mashayekhi K, Ferenc M, Hengstenberg C and Toma A. Left Main Coronary Artery Disease and Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions. J Clin Med. 2020;9.
  55. Wicik Z, Eyileten C, Jakubik D, Simoes SN, Martins DC, Jr., Pavao R, SILLER-MATULA JM and Postula M. ACE2 Interaction Networks in COVID-19: A Physiological Framework for Prediction of Outcome in Patients with Cardiovascular Risk Factors. J Clin Med. 2020;9.
  56. Verma SS, Bergmeijer TO, Gong L, Reny JL, Lewis JP, Mitchell BD, Alexopoulos D, Aradi D, Altman RB, Bliden K, Bradford Y, Campo G, Chang K, Cleator JH, Dery JP, Dridi NP, Fernandez-Cadenas I, Fontana P, Gawaz M, Geisler T, Gensini GF, Giusti B, Gurbel PA, Hochholzer W, Holmvang L, Kim EY, Kim HS, Marcucci R, Montaner J, Backman JD, Pakyz RE, Roden DM, Schaeffeler E, Schwab M, Shin JG, SILLER-MATULA JM, Ten Berg JM, Trenk D, Valgimigli M, Wallace J, Wen MS, Kubo M, Lee MTM, Whaley R, Winter S, Klein TE, Shuldiner AR, Ritchie MD and Investigators I. Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Clin Pharmacol Ther. 2020;108:1067-1077.
  57. Tripolt NJ, Kolesnik E, Pferschy PN, Verheyen N, Ablasser K, Sailer S, Alber H, Berger R, Kaulfersch C, Leitner K, Lichtenauer M, Mader A, Moertl D, Oulhaj A, Reiter C, Rieder T, Saely CH, SILLER-MATULA J, Weidinger F, Zechner PM, von Lewinski D, Sourij H and group Es. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial. Am Heart J. 2020;221:39-47.
  58. Traby L, Kollars M, Kaider A, SILLER-MATULA JM, Wolkersdorfer MF, Wolzt M, Kyrle PA and Eichinger S. Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers. Clin Pharmacol Ther. 2020;107:415-422.
  59. Tleyjeh IM, Bin Abdulhak AA, Tlayjeh H, Al-Mallah MH, Sohail MR, Hassett LC, SILLER-MATULA JM and Kashour T. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease: A Systematic Review and Meta-Analysis. Am J Ther. 2020;29:e74-e84.
  60. Soplinska A, Zareba L, Wicik Z, Eyileten C, Jakubik D, SILLER-MATULA JM, De Rosa S, Malek LA and Postula M. MicroRNAs as Biomarkers of Systemic Changes in Response to Endurance Exercise-A Comprehensive Review. Diagnostics (Basel). 2020;10.
  61. SILLER-MATULA JM, Mascherbauer J and Hengstenberg C. Editorial: Antithrombotic Treatment in Transcatheter Structural Cardiac Interventions and After Cardiac Device Implantation. Front Cardiovasc Med. 2020;7:616638.
  62. SILLER-MATULA JM and Mamas MA. Prediction for Contrast Volume in Transcatheter Aortic Valve Replacement – Important but Modifiable? Cardiology. 2020;145:611-614.
  63. Schnaubelt S, Breyer MK, SILLER-MATULA J and Domanovits H. Atrial fibrillation: a risk factor for unfavourable outcome in COVID-19? A case report. Eur Heart J Case Rep. 2020;4:1-6.
  64. Ravindran R, Kwok CS, Wong CW, SILLER-MATULA JM, Parwani P, Velagapudi P, Fischman DL, Alraies C, Michos ED and Mamas MA. Cardiac arrest and related mortality in emergency departments in the United States: Analysis of the nationwide emergency department sample. Resuscitation. 2020;157:166-173.
  65. Pietrzykowski L, Michalski P, Kosobucka A, Kasprzak M, Fabiszak T, Stolarek W, SILLER-MATULA JM and Kubica A. Medication adherence and its determinants in patients after myocardial infarction. Sci Rep. 2020;10:12028.
  66. Patti G, Pecen L, Manu MC, Huber K, Rohla M, Renda G, SILLER-MATULA J, Ricci F, Kirchhof P and Caterina R. Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. Int J Cardiol. 2020;318:67-73.
  67. Nitsche C, Aschauer S, Kammerlander AA, Schneider M, Poschner T, Duca F, Binder C, Koschutnik M, Stiftinger J, Goliasch G, SILLER-MATULA J, Winter MP, Anvari-Pirsch A, Andreas M, Geppert A, Beitzke D, Loewe C, Hacker M, Agis H, Kain R, Lang I, Bonderman D, Hengstenberg C and Mascherbauer J. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. Eur J Heart Fail. 2020;22:1852-1862.
  68. Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, Dery JP, Pakyz RE, Gong L, Ryan K, Kim EY, Aradi D, Fernandez-Cadenas I, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Gawaz M, Bliden KP, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, SILLER-MATULA JM, Ten Berg JM, Gurbel PA, Schwab M, Klein TE, Shuldiner AR and Investigators I. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. Eur Heart J Cardiovasc Pharmacother. 2020;6:203-210.
  69. Kubica J, Adamski P, Niezgoda P, Alexopoulos D, Badariene J, Budaj A, Buszko K, Dudek D, Fabiszak T, Gasior M, Gil R, Gorog DA, Grajek S, Gurbel PA, Gruchala M, Jaguszewski MJ, James S, Jeong YH, Jilma B, Kasprzak JD, Kleinrok A, Kubica A, Kuliczkowski W, Legutko J, Lesiak M, SILLER-MATULA JM, Nadolny K, Pstragowski K, Di Somma S, Specchia G, Stepinska J, Tantry US, Tycinska A, Verdoia M, Wojakowski W and Navarese EP. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiol J. 2020;27:661-676.
  70. Kozinski M, Rejszel-Baranowska J, Mlodawska E, SILLER-MATULA JM and Tomaszuk-Kazberuk A. Updated overview of evidence on optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutanous coronary intervention. Postepy Kardiol Interwencyjnej. 2020;16:127-137.
  71. Kovacevic KD, Jilma B, Zhu S, Gilbert JC, Winter MP, Toma A, Hengstenberg C, Lang I, Kubica J and SILLER-MATULA JM. von Willebrand Factor Predicts Mortality in ACS Patients Treated with Potent P2Y12 Antagonists and is Inhibited by Aptamer BT200 Ex Vivo. Thromb Haemost. 2020;120:1282-1290.
  72. Konigsbrugge O, Schmaldienst S, Auinger M, Klauser-Braun R, Lorenz M, Tabernig S, Kletzmayr J, Enzenberger B, Eigner M, Hecking M, SILLER-MATULA JM, Pabinger I, Saemann M and Ay C. Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysis. Atherosclerosis. 2020;298:1-6.
  73. Hofer F, Hengstenberg C, Goliasch G, Grygier M, Mascherbauer J and SILLER-MATULA JM. Transcatheter versus surgical aortic valve replacement in low-risk patients: a meta-analysis of randomized trials. Clin Res Cardiol. 2020;109:761-775.
  74. Hengstenberg C, Thoenes M, Bramlage P, SILLER-MATULA J and Mascherbauer J. Aortic valve stenosis awareness in Austria-results of a nationwide survey in 1001 subjects. Wien Med Wochenschr. 2020;170:141-149.
  75. Haider A, Bengs S, Luu J, Osto E, SILLER-MATULA JM, Muka T and Gebhard C. Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome. Eur Heart J. 2020;41:1328-1336.
  76. Gue YX, Spinthakis N, Farag M, Kubica J, SILLER-MATULA JM, Srinivasan M and Gorog DA. Impact of Preadmission Morphine on Reinfarction in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention: A Meta-Analysis. Clin Pharmacol Ther. 2020;108:54-62.
  77. Gasecka A, Nieuwland R, Budnik M, Dignat-George F, Eyileten C, Harrison P, Lacroix R, Leroyer A, Opolski G, Pluta K, van der Pol E, Postula M, Siljander P, SILLER-MATULA JM and Filipiak KJ. Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel. J Thromb Haemost. 2020;18:609-623.
  78. Gager GM, Jilma B, Winter MP, Hengstenberg C, Lang IM, Toma A, Pruller F, Wallner M, Kolesnik E, von Lewinski D and SILLER-MATULA JM. Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients. Eur J Clin Invest. 2020;50:e13304.
  79. Gager GM, Biesinger B, Hofer F, Winter MP, Hengstenberg C, Jilma B, Eyileten C, Postula M, Lang IM and SILLER-MATULA JM. Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome. Vascul Pharmacol. 2020;135:106806.
  80. Eyileten C, Postula M, Jakubik D, Toma A, Mirowska-Guzel D, Patti G, Renda G and SILLER-MATULA JM. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type. J Clin Med. 2020;9.
  81. Winter MP, von Lewinski D, Wallner M, Pruller F, Kolesnik E, Hengstenberg C and SILLER-MATULA JM. Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS – SWITCH study. Sci Rep. 2019;9:8194.
  82. Winter MP, Schneeweiss T, Cremer R, Biesinger B, Hengstenberg C, Pruller F, Wallner M, Kolesnik E, von Lewinski D, Lang IM and SILLER-MATULA JM. Platelet reactivity patterns in patients treated with dual antiplatelet therapy. Eur J Clin Invest. 2019:e13102.
  83. SILLER-MATULA JM, Hofer F, Goliasch G, Andreas M, Mascherbauer J and Hengstenberg C. [Aortic valve disease]. MMW Fortschr Med. 2019;161:42-46.
  84. Rohla M, Weiss TW, Pecen L, Patti G, SILLER-MATULA JM, Schnabel RB, Schilling R, Kotecha D, Lucerna M, Huber K, De Caterina R and Kirchhof P. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events – European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open. 2019;9:e022478.
  85. Renda G, Patti G, Lang IM, SILLER-MATULA JM, Hylek EM, Ambrosio G, Haas S, De Caterina R and Working Group on Thrombosis of the Italian Society of C. Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. Int J Cardiol. 2019;286:198-207.
  86. Pordzik J, Jakubik D, Jarosz-Popek J, Wicik Z, Eyileten C, De Rosa S, Indolfi C, SILLER-MATULA JM, Czajka P and Postula M. Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review. Cardiovasc Diabetol. 2019;18:113.
  87. Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, SILLER-MATULA J, Ricci F, Kirchhof P and De Caterina R. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. Am J Med. 2019;132:749-757 e5.
  88. Ostrowska M, Kubica J, Adamski P, Kubica A, Eyileten C, Postula M, Toma A, Hengstenberg C and SILLER-MATULA JM. Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. Front Cardiovasc Med. 2019;6:176.
  89. Kubica A, Kosobucka A, Fabiszak T, Gorog DA and SILLER-MATULA JM. Assessment of adherence to medication in patients after myocardial infarction treated with percutaneous coronary intervention. Is there a place for newself-reported questionnaires? Curr Med Res Opin. 2019;35:341-349.
  90. Komosa A, Perek B, Rzymski P, Lesiak M, SILLER-MATULA JM, Grygier M, Puslecki M, Misterski M, Olasinska-Wisniewska A, Ropacka-Lesiak M, Krasinski Z, Niedzielski P, Mularek-Kubzdela T and Poniedzialek B. Transcatheter Aortic Valve Replacement Is Associated with Less Oxidative Stress and Faster Recovery of Antioxidant Capacity than Surgical Aortic Valve Replacement. J Clin Med. 2019;8.
  91. Komosa A, Lesiak M, Krasinski Z, Grygier M, Siniawski A, Skorupski W, Olasinska-Wisniewska A, Pyda M, Araszkiewicz A, Mitkowski P, Grajek S, Mularek-Kubzdela T, Hengstenberg C and SILLER-MATULA JM. Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis. Thromb Haemost. 2019;119:1000-1020.
  92. Jezewski MP, Kubisa MJ, Eyileten C, De Rosa S, Christ G, Lesiak M, Indolfi C, Toma A, SILLER-MATULA JM and Postula M. Bioresorbable Vascular Scaffolds-Dead End or Still a Rough Diamond? J Clin Med. 2019;8.
  93. Humenberger M, Stockinger M, Kettner S, SILLER-MATULA J and Hajdu S. Impact of Antiplatelet Therapies on Patients Outcome in Osteosynthetic Surgery of Proximal Femoral Fractures. J Clin Med. 2019;8.
  94. Hengstenberg C and SILLER-MATULA JM. Shedding Light on Long-Term Effects of Early Antiplatelet Strategies After Fibrinolytic Treatment in STEMI. J Am Coll Cardiol. 2019;73:2829-2831.
  95. Gelbenegger G, Postula M, Pecen L, Halvorsen S, Lesiak M, Schoergenhofer C, Jilma B, Hengstenberg C and SILLER-MATULA JM. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. BMC Med. 2019;17:198.
  96. Gasecka A, Konwerski M, Pordzik J, Soplinska A, Filipiak KJ, SILLER-MATULA JM and Postula M. Switching between P2Y12 antagonists – From bench to bedside. Vascul Pharmacol. 2019;115:1-12.
  97. Eyileten C, Soplinska A, Pordzik J, SILLER-MATULA JM and Postula M. Effectiveness of Antiplatelet Drugs Under Therapeutic Hypothermia: A Comprehensive Review. Clin Pharmacol Ther. 2019;106:993-1005.
  98. SILLER-MATULA JM, Pecen L, Patti G, Lucerna M, Kirchhof P, Lesiak M, Huber K, Verheugt FWA, Lang IM, Renda G, Schnabel RB, Wachter R, Kotecha D, Sellal JM, Rohla M, Ricci F, De Caterina R and group TiA. Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF – HF substudy. Int J Cardiol. 2018;265:141-147.
  99. Sikora J, Niezgoda P, Baranska M, Buszko K, Skibinska N, Sroka W, Pstragowski K, SILLER-MATULA J, Bernd J, Gorog D, Navarese EP, Marszall MP and Kubica J. METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectorIS-The METAMORPHOSIS Trial. Thromb Haemost. 2018;118:2126-2133.
  100. Schoergenhofer C, Hobl EL, Schellongowski P, Heinz G, Speidl WS, SILLER-MATULA JM, Schmid M, Sunder-Plassmann R, Stimpfl T, Hackl M and Jilma B. Clopidogrel in Critically Ill Patients. Clin Pharmacol Ther. 2018;103:217-223.
  101. Pruller F, Milke OL, Bis L, Fruhwald F, Scherr D, Eller P, Patzold S, Altmanninger-Sock S, Rainer P, SILLER-MATULA J and von Lewinski D. Impaired aspirin-mediated platelet function inhibition in resuscitated patients with acute myocardial infarction treated with therapeutic hypothermia: a prospective, observational, non-randomized single-centre study. Ann Intensive Care. 2018;8:28.
  102. Pruller F, Bis L, Milke OL, Fruhwald F, Patzold S, Altmanninger-Sock S, SILLER-MATULA J, von Lewinski F, Ablasser K, Sacherer M and von Lewinski D. Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients. J Clin Med. 2018;7.
  103. Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, SILLER-MATULA J, Schnabel RB, Cemin R, Kirchhof P and De Caterina R. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy – A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. Int J Cardiol. 2018;270:160-166.
  104. Milanowski L, Rasul F, Gajda SN, Eyileten C, SILLER-MATULA J and Postula M. Genetic Variability of SRC Family Kinases and Its Association with Platelet Hyperreactivity and Clinical Outcomes: A Systematic Review. Curr Pharm Des. 2018;24:628-640.
  105. Kubisa MJ, Jezewski MP, Gasecka A, SILLER-MATULA JM and Postula M. Ticagrelor – toward more efficient platelet inhibition and beyond. Ther Clin Risk Manag. 2018;14:129-140.
  106. Kubica J, Adamski P, Paciorek P, Ladny JR, Kalarus Z, Banasiak W, Kochman W, Goracy J, Wozakowska-Kaplon B, Navarese EP, Kleinrok A, Gil R, Lesiak M, Drozdz J, Kubica A, Filipiak KJ, Kazmierczak J, Goch A, Grajek S, Basinski A, Szarpak L, Grzesk G, Hoffman P, Wojakowski W, Gasior Z, Dobrzycki S, SILLER-MATULA JM, Witkowski A, Kuliczkowski W, Gruchala M, Timler D, Opolski G, Dudek D, Legutko J, Zielinska M and Wojcik J. Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts‘ standpoint. Cardiol J. 2018;25:291-300.
  107. Hengstenberg C and SILLER-MATULA JM. Coming Closer to Personalized Medicine in Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2018;11:1730-1732.
  108. Bergmeijer TO, Reny JL, Pakyz RE, Gong L, Lewis JP, Kim EY, Aradi D, Fernandez-Cadenas I, Horenstein RB, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Dery JP, Gawaz M, Bliden K, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Simon T, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, SILLER-MATULA JM, Ten Berg JM, Gurbel PA, Hulot JS, Mitchell BD, Schwab M, Ritchie MD, Klein TE, Shuldiner AR and Investigators I. Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). Am Heart J. 2018;198:152-159.
  109. Winter MP, Grove EL, De Caterina R, Gorog DA, Ahrens I, Geisler T, Gurbel PA, Tantry U, Navarese EP and SILLER-MATULA JM. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Eur Heart J Cardiovasc Pharmacother. 2017;3:221-234.
  110. SILLER-MATULA JM, Petre A, Delle-Karth G, Huber K, Ay C, Lordkipanidze M, De Caterina R, Kolh P, Mahla E and Gersh BJ. Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care. 2017;6:753-770.
  111. SILLER-MATULA J, Lang IM, Schoergenhofer C, Roest M and Jilma B. Interdependence between osteoprotegerin and active von Willebrand factor in long-term cardiovascular mortality prediction in patients undergoing percutaneous coronary intervention. Thromb Haemost. 2017;117:1730-1738.
  112. Schoergenhofer C, Hobl EL, Staudinger T, Speidl WS, Heinz G, SILLER-MATULA J, Zauner C, Reiter B, Kubica J and Jilma B. Prasugrel in critically ill patients. Thromb Haemost. 2017;117:1582-1587.
  113. Patti G, Lucerna M, Pecen L, SILLER-MATULA JM, Cavallari I, Kirchhof P and De Caterina R. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation). J Am Heart Assoc. 2017;6.
  114. Niezgoda P, Sikora J, Baranska M, Sikora A, Buszko K, Sieminska E, Marszall MP, SILLER-MATULA JM, Jilma B, Alexopoulos D, Fabiszak T and Kubica J. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. Thromb Haemost. 2017;117:718-726.
  115. Navarese EP, Kolodziejczak M, Winter MP, Alimohammadi A, Lang IM, Buffon A, Lip GY and SILLER-MATULA JM. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. Int J Cardiol. 2017;227:644-649.
  116. Kubica J, Adamski P, Paciorek P, Ladny JR, Kalarus Z, Banasiak W, Kochman W, Goracy J, Wozakowska-Kaplon B, Navarese EP, Kleinrok A, Gil R, Lesiak M, Drozdz J, Kubica A, Filipiak KJ, Kazmierczak J, Goch A, Grajek S, Basinski A, Szarpak L, Grzesk G, Hoffman P, Wojakowski W, Gasior Z, Dobrzycki S, SILLER-MATULA JM, Witkowski A, Kuliczkowski W, Gruchala M, Timler D, Opolski G, Dudek D, Legutko J, Zielinska M and Wojcik J. Anti-aggregation therapy in patients with acute coronary syndrome – recommendations for medical emergency teams. Experts‘ standpoint. Kardiol Pol. 2017;75:399-408.
  117. Komosa A, Rzymski P, Perek B, Ropacka-Lesiak M, Lesiak M, SILLER-MATULA JM and Poniedzialek B. Platelets redox balance assessment: Current evidence and methodological considerations. Vascul Pharmacol. 2017;93-95:6-13.
  118. SILLER-MATULA JM, Specht S, Kubica J, Alexopoulos D, De Caterina R, Hobl EL, Jilma B, Christ G and Lang IM. Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients. Br J Clin Pharmacol. 2016;82:1343-1350.
  119. SILLER-MATULA JM, Hintermeier A, Kastner J, Kreiner G, Maurer G, Kratochwil C, Lang IM and Delle-Karth G. Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor. Vascul Pharmacol. 2016;79:6-10.
  120. SILLER-MATULA JM, Akca B, Neunteufl T, Maurer G, Lang IM, Kreiner G, Berger R and Delle-Karth G. Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor. Platelets. 2016;27:373-7.
  121. Kubica J, Kubica A, Jilma B, Adamski P, Hobl EL, Navarese EP, SILLER-MATULA JM, Dabrowska A, Fabiszak T, Kozinski M and Gurbel PA. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol. 2016;215:201-8.
  122. Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, SILLER-MATULA JM, Marszall MP, Rosc D and Kozinski M. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016;37:245-52.
  123. Komosa A, SILLER-MATULA JM, Lesiak M, Michalak M, Kowal J, Maczynski M, Siniawski A, Mularek-Kubzdela T, Wisniewski S and Grajek S. Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention. Thromb Res. 2016;138:49-54.
  124. Winter MP, Kozinski M, Kubica J, Aradi D and SILLER-MATULA JM. Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej. 2015;11:259-80.
  125. SILLER-MATULA JM, Trenk D, Schror K, Gawaz M, Kristensen SD, Storey RF, Huber K and European Platelet A. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors–is an algorithm the answer? Thromb Haemost. 2015;113:37-52.
  126. SILLER-MATULA JM, Gruber C, Francesconi M, Dechant C, Jilma B, Delle-Karth G, Grohs K, Podczeck-Schweighofer A and Christ G. The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Sci (Lond). 2015;128:121-30.
  127. Ozsoy M, Klatte T, Wiener H, SILLER-MATULA J and Schmidbauer J. Intraoperative imprint cytology for real-time assessment of surgical margins during partial nephrectomy: A comparison with frozen section. Urol Oncol. 2015;33:67 e25-9.
  128. Komosa A, SILLER-MATULA JM, Kowal J, Lesiak M, Siniawski A, Maczynski M, Michalak M, Mularek-Kubzdela T and Grajek S. Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb. Platelets. 2015;26:43-7.
  129. Droppa M, Tschernow D, Muller KA, Tavlaki E, Karathanos A, Stimpfle F, Schaeffeler E, Schwab M, Tolios A, SILLER-MATULA JM, Gawaz M and Geisler T. Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). PLoS One. 2015;10:e0121620.
  130. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, ten Berg J, Janssen P, Angiolillo DJ, SILLER-MATULA JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW and Sibbing D. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015;36:1762-71.
  131. SILLER-MATULA JM, Trenk D, Krahenbuhl S, Michelson AD and Delle-Karth G. Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. J Thromb Haemost. 2014;12:2-13.
  132. SILLER-MATULA JM, Lang IM, Neunteufl T, Kozinski M, Maurer G, Linkowska K, Grzybowski T, Kubica J and Jilma B. Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention. PLoS One. 2014;9:e102701.
  133. SILLER-MATULA JM and Delle Karth G. [Dual platelet inhibitors in intensive care units]. Med Klin Intensivmed Notfmed. 2014;109:429-36.
  134. SILLER-MATULA JM, Arbesu I, Jilma B, Maurer G, Lang IM and Mannhalter C. Association between the rs342293 polymorphism and adverse cardiac events in patients undergoing percutaneous coronary intervention. Thromb Haemost. 2014;111:1060-6.
  135. Kubica J, Kozinski M, Navarese EP, Tantry U, Kubica A, SILLER-MATULA JM, Jeong YH, Fabiszak T, Andruszkiewicz A and Gurbel PA. Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Curr Med Res Opin. 2014;30:813-28.
  136. Kubica A, Kasprzak M, SILLER-MATULA J, Kozinski M, Pio Navarese E, Obonska K, Andruszkiewicz A, Sztuba B, Fabiszak T, Swiatkiewicz I, Paciorek P and Kubica J. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J Pharmacol. 2014;742:47-54.
  137. Kozinski M, Obonska K, Stankowska K, Navarese EP, Fabiszak T, Stolarek W, Kasprzak M, SILLER-MATULA JM, Rosc D, Kubica J and De Servi S. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiol J. 2014;21:547-56.
  138. Gouya G, SILLER-MATULA JM, Fritzer-Szekeres M, Neuhold S, Storka A, Neuhofer LM, Clodi M, Hulsmann M, Pacher R and Wolzt M. Association of endostatin with mortality in patients with chronic heart failure. Eur J Clin Invest. 2014;44:125-35.
  139. Gouya G, Arrich J, Wolzt M, Huber K, Verheugt FW, Gurbel PA, Pirker-Kees A and SILLER-MATULA JM. Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Stroke. 2014;45:492-503.
  140. Christ G, SILLER-MATULA JM, Francesconi M, Dechant C, Grohs K and Podczeck-Schweighofer A. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ Open. 2014;4:e005781.
  141. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, SILLER-MATULA J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA and Working Group on On-Treatment Platelet R. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261-73.
  142. SILLER-MATULA JM, Trenk D, Schror K, Gawaz M, Kristensen SD, Storey RF, Huber K and Epa. Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv. 2013;6:1111-28.
  143. SILLER-MATULA JM and Jilma B. Why have studies of tailored anti-platelet therapy failed so far? Thromb Haemost. 2013;110:628-31.
  144. SILLER-MATULA JM, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G, Gouya G, Ruzicka K, Podczeck-Schweighofer A and Christ G. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol. 2013;167:2018-23.
  145. SILLER-MATULA JM, Delle-Karth G, Christ G, Neunteufl T, Maurer G, Huber K, Tolios A, Drucker C and Jilma B. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol. 2013;167:430-5.
  146. Christ G, Hafner T, SILLER-MATULA JM, Francesconi M, Grohs K, Wilhelm E and Podczeck-Schweighofer A. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy. Thromb Res. 2013;132:e36-41.
  147. Steinhauser G, Adlassnig W, Risch JA, Anderlini S, Arguriou P, Armendariz AZ, Bains W, Baker C, Barnes M, Barnett J, Baumgartner M, Baumgartner T, Bendall CA, Bender YS, Bichler M, Biermann T, Bini R, Blanco E, Bleau J, Brink A, Brown D, Burghuber C, Calne R, Carter B, Castano C, Celec P, Celis ME, Clarke N, Cockrell D, Collins D, Coogan B, Craig J, Crilly C, Crowe D, Csoka AB, Darwich C, Del Kebos T, Derinaldi M, Dlamini B, Drewa T, Dwyer M, Eder F, de Palma RE, Esmay D, Rott CE, Exley C, Falkov R, Farber CI, Fearn W, Felsmann S, Flensmark J, Fletcher AK, Foster M, Fountoulakis KN, Fouratt J, Blanca JG, Sotelo MG, Gittler F, Gittler G, Gomez J, Gomez JF, Polar MG, Gonzalez J, Gosselsberger C, Habermacher L, Hajek M, Hakala F, Haliburton MS, Hankins JR, Hart J, Hasslberger S, Hennessey D, Herrmann A, Hersee M, Howard C, Humphries S, Isharc L, Ivanovski P, Jenuth S, Jerndal J, Johnson C, Keleta Y, Kenny A, Kidd B, Kohle F, Kolahi J, Koller-Peroutka M, Kostova L, Kumar A, Kurosawa A, Lance T, Lechermann M, Lendl B, Leuchters M, Lewis E, Lieb E, Lloyd G, Losek A, Lu Y, Maestracci S, Mangan D, Mares AW, Barnett JM, McClain V, McNair JS, Michael T, Miller L, Monzani P, Moran B, Morris M, Mossmer G, Mountain J, Phuthe OM, Munoz M, Nakken S, Wambui AN, Neunteufl B, Nikolic D, Oberoi DV, Obmode G, Ogar L, Ohara J, Rybine NO, Owen B, Owen KW, Parikh R, Pearce NJ, Pemmer B, Piper C, Prince I, Reid T, Rindermann H, Risch S, Robbins J, Roberts S, Romero A, Rothe MT, Ruiz S, Sacher J, Sackl W, Salletmaier M, Sanand J, Sauerzopf C, Schwarzgruber T, Scott D, Seegers L, Seppi D, Shields K, SILLER-MATULA J, Singh B, Sithole S, Six F, Skoyles JR, Slofstra J, Sole DA, Sommer WF, Sonko M, Starr-Casanova CJ, Steakley ME, Steinhauser W, Steinhoff K, Sterba JH, Steppan M, Stindl R, Stokely J, Stokely K, St-Pierre G, Stratford J, Streli C, Stryg C, Sullivan M, Summhammer J, Tadesse A, Tavares D, Thompson L, Tomlinson A, Tozer J, Trevisanato SI, Trimmel M, Turner N, Vahur P, van der Byl J, van der Maas T, Varela L, Vega CA, Vermaak S, Villasenor A, Vogel M, von Wintzigerode G, Wagner C, Weinberger M, Weinberger P, Wilson N, Wolfe JF, Woodley MA, Young I, Zuraw G and Zwiren N. Peer review versus editorial review and their role in innovative science. Theor Med Bioeth. 2012;33:359-76.
  148. Spiel AO, Derhaschnig U, Schwameis M, Bartko J, SILLER-MATULA JM and Jilma B. Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial. Clin Sci (Lond). 2012;123:591-600.
  149. SILLER-MATULA JM, Miller I, Gemeiner M, Plasenzotti R, Bayer G, Mesteri I, Fabry A, Petroczi K, Nobauer K, Razzazi-Fazeli E, Planchon S, Renaut J, Quehenberger P, Selzer E and Jilma B. Continuous thrombin infusion leads to a bleeding phenotype in sheep. Thromb Res. 2012;130:226-36.
  150. SILLER-MATULA JM, Merhi Y, Tanguay JF, Duerschmied D, Wagner DD, McGinness KE, Pendergrast PS, Chung JK, Tian X, Schaub RG and Jilma B. ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. Arterioscler Thromb Vasc Biol. 2012;32:902-9.
  151. SILLER-MATULA JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K and Jilma B. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost. 2012;10:529-42.
  152. SILLER-MATULA JM. Hemorrhagic complications associated with aspirin: an underestimated hazard in clinical practice? JAMA. 2012;307:2318-20.
  153. Schror K, SILLER-MATULA JM and Huber K. Pharmacokinetic basis of the antiplatelet action of prasugrel. Fundam Clin Pharmacol. 2012;26:39-46.
  154. Heinisch BB, Vcelar B, Kapiotis S, Blann A, Wolzt M, SILLER-MATULA JM and Jilma B. The effect of erythropoietin on platelet and endothelial activation markers: a prospective trial in healthy volunteers. Platelets. 2012;23:352-8.
  155. Grzesk G, Kozinski M, Navarese EP, Krzyzanowski M, Grzesk E, Kubica A, SILLER-MATULA JM, Castriota F and Kubica J. Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats. Thromb Res. 2012;130:65-9.
  156. Yukhanyan L, Freynhofer MK, SILLER-MATULA J, Schror K and Huber K. Genetic variability in response to clopidogrel therapy and its clinical implications. Thromb Haemost. 2011;105 Suppl 1:S55-9.
  157. Tentzeris I, SILLER-MATULA J, Farhan S, Jarai R, Wojta J and Huber K. Platelet function variability and non-genetic causes. Thromb Haemost. 2011;105 Suppl 1:S60-6.
  158. Spiel AO, Bartko J, Schwameis M, Firbas C, SILLER-MATULA J, Schuetz M, Weigl M and Jilma B. Increased platelet aggregation and in vivo platelet activation after granulocyte colony-stimulating factor administration. A randomised controlled trial. Thromb Haemost. 2011;105:655-62.
  159. SILLER-MATULA JM, Schwameis M, Blann A, Mannhalter C and Jilma B. Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects. Thromb Haemost. 2011;106:1020-33.
  160. SILLER-MATULA JM, Huber K, Christ G, Schror K, Kubica J, Herkner H and Jilma B. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Heart. 2011;97:98-105.
  161. SILLER-MATULA JM and Delle-Karth G. Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding. Evid Based Med. 2011;16:144-5.
  162. Navarese EP, De Luca G, Castriota F, Kozinski M, Gurbel PA, Gibson CM, Andreotti F, Buffon A, SILLER-MATULA JM, Sukiennik A, De Servi S and Kubica J. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost. 2011;9:1902-15.
  163. Kozinski M, Bielis L, Wisniewska-Szmyt J, Boinska J, Stolarek W, Marciniak A, Kubica A, Grabczewska Z, Navarese EP, Andreotti F, SILLER-MATULA JM, Rosc D and Kubica J. Diurnal variation in platelet inhibition by clopidogrel. Platelets. 2011;22:579-87.
  164. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, SILLER-MATULA J, Gilbert JC and Knobl P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;105:545-52.
  165. Tentzeris I, Jarai R, Farhan S, Brozovic I, Smetana P, Geppert A, Wojta J, SILLER-MATULA J and Huber K. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost. 2010;104:1211-8.
  166. Spiel AO, SILLER-MATULA J, Firbas C, Leitner JM, Russmueller G and Jilma B. Single dose granulocyte colony-stimulating factor markedly enhances shear-dependent platelet function in humans. Platelets. 2010;21:464-9.
  167. SILLER-MATULA JM, Tentzeris I, Vogel B, Schacherl S, Jarai R, Geppert A, Unger G and Huber K. Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points. Clin Res Cardiol. 2010;99:645-50.
  168. SILLER-MATULA JM, Krumphuber J and Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol. 2010;159:502-17.
  169. SILLER-MATULA JM, Jilma B, Schror K, Christ G and Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:2624-41.
  170. SILLER-MATULA JM and Jilma B. Ticagrelor: from discovery to Phase III clinical trial. Future Cardiol. 2010;6:753-64.
  171. SILLER-MATULA JM, Christ G, Lang IM, Delle-Karth G, Huber K and Jilma B. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost. 2010;8:351-9.
  172. SILLER-MATULA JM, Bayer G, Bergmeister H, Quehenberger P, Petzelbauer P, Friedl P, Mesteri I and Jilma B. An experimental model to study isolated effects of thrombin in vivo. Thromb Res. 2010;126:454-61.
  173. Mayr FB, Knobl P, Jilma B, SILLER-MATULA JM, Wagner PG, Schaub RG, Gilbert JC and Jilma-Stohlawetz P. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion. 2010;50:1079-87.
  174. Firbas C, SILLER-MATULA JM and Jilma B. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther. 2010;8:1689-701.
  175. SILLER-MATULA JM, Spiel AO, Lang IM, Kreiner G, Christ G and Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157:148 e1-5.
  176. SILLER-MATULA JM, Haberl K, Prillinger K, Panzer S, Lang I and Jilma B. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. Thromb Res. 2009;123:874-80.
  177. SILLER-MATULA JM, Gouya G, Wolzt M and Jilma B. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost. 2009;102:397-403.
  178. Kasprzak M, Kozinski M, Bielis L, Boinska J, Plazuk W, Marciniak A, Budzynski J, SILLER-MATULA J, Rosc D and Kubica J. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J. 2009;16:535-44.
  179. SILLER-MATULA JM, Plasenzotti R, Spiel A, Quehenberger P and Jilma B. Interspecies differences in coagulation profile. Thromb Haemost. 2008;100:397-404.
  180. SILLER-MATULA JM, Panzer S and Jilma B. Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay. Platelets. 2008;19:551-4.
  181. SILLER-MATULA JM, Lang I, Christ G and Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008;52:1557-63.
  182. SILLER-MATULA JM and Jilma B. Strain differences in toxic effects of long-lasting isoflurane anaesthesia between Wistar rats and Sprague Dawley rats. Food Chem Toxicol. 2008;46:3550-2.
  183. SILLER-MATULA J, Schror K, Wojta J and Huber K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost. 2007;97:385-93.

Richtlinien für Ärzte

  1. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I, Geisler T, Hinterbuchner L, Ibanez B, Lenarczyk R, Mansmann UR, McGreavy P, Mueller C, Muneretto C, Niessner A, Potpara TS, Ristic A, Sade LE, Schirmer H, Schupke S, Sillesen H, Skulstad H, Torracca L, Tutarel O, Van Der Meer P, Wojakowski W, Zacharowski K, Group ESCSD, Knuuti J, Kristensen SD, Aboyans V, Ahrens I, Antoniou S, Asteggiano R, Atar D, Baumbach A, Baumgartner H, Bohm M, Borger MA, Bueno H, Celutkiene J, Chieffo A, Cikes M, Darius H, Delgado V, Devereaux PJ, Duncker D, Falk V, Fauchier L, Habib G, Hasdai D, Huber K, Iung B, Jaarsma T, Konradi A, Koskinas KC, Kotecha D, Landmesser U, Lewis BS, Linhart A, Lochen ML, Maeng M, Manzo-Silberman S, Mindham R, Neubeck L, Nielsen JC, Petersen SE, Prescott E, Rakisheva A, Saraste A, Sibbing D, SILLER-MATULA J, Sitges M, Stankovic I, Storey RF, Ten Berg J, Thielmann M and Touyz RM. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022, online first.
  2. Kubica J, Adamski P, Ladny JR, Kazmierczak J, Fabiszak T, Filipiak KJ, Gajda R, Gasior M, Gasior Z, Gil R, Goracy J, Grajek S, Gromadzinski L, Gruchala M, Grzesk G, Hoffman P, Jaguszewski MJ, Janion M, Jankowski P, Kalarus Z, Kasprzak JD, Kleinrok A, Kochman W, Kubica A, Kuliczkowski W, Legutko J, Lesiak M, Nadolny K, Navarese EP, Niezgoda P, Ostrowska M, Paciorek P, SILLER-MATULA J, Szarpak L, Timler D, Witkowski A, Wojakowski W, Wysokinski A and Zielinska M. Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022. Cardiol J. 2022.
  3. Gorog DA, Price S, Sibbing D, Baumbach A, Capodanno D, Gigante B, Halvorsen S, Huber K, Lettino M, Leonardi S, Morais J, Rubboli A, SILLER-MATULA JM, Storey RF, Vranckx P and Rocca B. Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a Joint Position Paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J Cardiovasc Pharmacother. 2020.
  4. Kubica J, Adamski P, Paciorek P, Ladny JR, Kalarus Z, Banasiak W, Kochman W, Goracy J, Wozakowska-Kaplon B, Navarese EP, Kleinrok A, Gil R, Lesiak M, Drozdz J, Kubica A, Filipiak KJ, Kazmierczak J, Goch A, Grajek S, Basinski A, Szarpak L, Grzesk G, Hoffman P, Wojakowski W, Gasior Z, Dobrzycki S, SILLER-MATULA JM, Witkowski A, Kuliczkowski W, Gruchala M, Timler D, Opolski G, Dudek D, Legutko J, Zielinska M and Wojcik J. Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts‘ standpoint. Cardiol J. 2018;25:291-300.
  5. Kubica J, Adamski P, Paciorek P, Ladny JR, Kalarus Z, Banasiak W, Kochman W, Goracy J, Wozakowska-Kaplon B, Navarese EP, Kleinrok A, Gil R, Lesiak M, Drozdz J, Kubica A, Filipiak KJ, Kazmierczak J, Goch A, Grajek S, Basinski A, Szarpak L, Grzesk G, Hoffman P, Wojakowski W, Gasior Z, Dobrzycki S, SILLER-MATULA JM, Witkowski A, Kuliczkowski W, Gruchala M, Timler D, Opolski G, Dudek D, Legutko J, Zielinska M and Wojcik J. Anti-aggregation therapy in patients with acute coronary syndrome – recommendations for medical emergency teams. Experts‘ standpoint. Kardiol Pol. 2017;75:399-408.
  6. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, SILLER-MATULA J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA and Working Group on On-Treatment Platelet R. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261-73.

 Editorials

  1. Patti G, SILLER-MATULA JM and Fedorowski A. Thrombosis and fibrinolysis in atherosclerotic cardiovascular disease: it takes two to tango? Eur Heart J. 2022; 43(10):982-984.
  2. SILLER-MATULA JM and Shah B. Sex Differences in Treatment and Outcomes in Non-ST-Elevation Acute Coronary Syndrome: A Persistent Disparity. Circ Cardiovasc Interv. 2021;14:e010329.
  3. SILLER-MATULA JM and Shah B. Sex Differences in Treatment and Outcomes in Non-ST-Elevation Acute Coronary Syndrome: A Persistent Disparity. Circ Cardiovasc Interv. 2021;14:e010329.
  4. SILLER-MATULA JM and Mamas MA. Prediction for Contrast Volume in Transcatheter Aortic Valve Replacement – Important but Modifiable? Cardiology. 2020:1-3.
  5. Hengstenberg C and SILLER-MATULA Shedding Light on Long-Term Effects of Early Antiplatelet Strategies After Fibrinolytic Treatment in STEMI. J Am Coll Cardiol. 2019;73:2829-2831.
  6. Hengstenberg C and SILLER-MATULA Coming Closer to Personalized Medicine in Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2018;11:1730-1732.
  7. SILLER-MATULA Hemorrhagic complications associated with aspirin: an underestimated hazard in clinical practice? JAMA. 2012;307:2318-20.

Buch Kapiteln

  1. SILLER-MATULA J, Huber K. Klinische Studien mit neuen Plättchenfunktionshemmern in K. Schrör & W. Kirch (eds) Pharmakologie und Klinik neuer Antiplättchensubstanzen. Schattauer 2013:23-46.
  2. Huber K, SILLER-MATULA J, Schrör K. Antiplättchentherapie -aktueller Stand und zukünftige Entwicklungen in K. Schrör & W. Kirch (eds) Pharmakologie und Klinik neuer Antiplättchensubstanzen. Schattauer 2013:155-164.
  3. SILLER-MATULA Der Thrombozyt beim ACS. in Alber H. (eds) Thrombozytenhemmung beim akuten Koronarsyndrom. Unimed Verlag 2012:31-40.

In deutscher Sprache

  1. Gager GM, SILLER-MATULA Update vom ESC 2021: Antithrombotische Therapie. Universum Innere Medizin 2021; 8:1-3.
  2. Gager GM, SILLER-MATULA Herzohrverschluss als Alternative zur oralen Antikoagulation bei Vorhofflimmern. Jatros Kardiol 2021; 9:3-6.
  3. Gager GM, SILLER-MATULA Pleiotrope Effekte von neuen oralen Antikoagulantien / Pleiotropic effects of NOACS. J Kardiol 2019;26:1-4.
  4. Mascherbauer J, Goliasch G. SILLER-MATULA Schneider M. Aktueller Therapiestand bei Herzklappenerkrankungen CliniCum 2019; 7–8/19.
  5. SILLER-MATULA Antikoagulation plus Plättchenhemmung: Welche Kombination zeigt Vorteile in der AUGUSTUS-Studie? Universum Innere Medizin 2019;04:80-81.
  6. Hofer F, Hengstenberg C, SILLER-MATULA Antithrombotische Therapie nach TAVI. J Kardiol 2018;26:126-31.
  7. Winter MP, SILLER-MATULA Was empfehlen die Guidelines? NSTEMI – welche Antiplättchentherapie für wen? Jatros: Kardiologie & Gefäßmedizin 2016;3:62-64.
  8. SILLER-MATULA Vorbehandlung mit P2Y12-Rezeptorinhibitoren bei Patienten mit NSTE-ACS. J Kardiol 2015;22:7-8.
  9. Specht S, SILLER-MATULA NSTE-ACS bei VHF: Management bei vorbestehender Therapie mit DOAK. Jatros: Kardiologie & Gefäßmedizin 2014;3:24-25.
  10. SILLER-MATULA Akutes Koronarsyndrom: Entscheidungskriterien für die Wahl des Plättchenhemmers. Arzt und Praxis 2014;68:18-20.
  11. SILLER-MATULA Prasugrel: Management des ACS- Patienten mit Diabetes. Universum Innere Medizin 2013;08:32-33.
  12. SILLER-MATULA Management des Diabetes-ACS-Patienten mit Prasugrel. J Hyperton 2013;17:168-9.
  13. SILLER-MATULA Nutzen-Risiko-Profil von Aspirin in der Primär- und Sekundärprävention. J Hyperton 2013;17:117-8.
  14. Akca B, SILLER-MATULA Platelet Function Testing: Expectations and Reality. J Kardiol 2013;20:160–7.
  15. SILLER-MATULA Das Ansprechen auf die Plättchenhemmung messen: Individualisierte Anti-Plättchen-Therapie. Universum Innere Medizin 2012;09:45-46.
  16. SILLER-MATULA Individualisierte Anti-Plättchen-Therapie. Universum Innere Medizin 2012;8:32-33.
  17. SILLER-MATULA Thrombozytenaggregationshemmung: Nicht alle Patienten sind gleich. Universum Innere Medizin 2012;7:18.
  18. SILLER-MATULA Protonenpumpenhemmer 2011: Gut für den Magen, schlecht für das Herz? Universum Innere Medizin 2011;8:10.
  19. Jilma B, SILLER-MATULA Ticagrelor zur Behandlung des akuten Koronarsydroms. Pharmainformation 2011;26:2.
  20. SILLER-MATULA JM, Firbas C, Jilma B. Plättchenaggregationshemmer-Kontrolle der Wirkung: wie und bei wem? Universum Innere Medizin 2010;08:66-67.
  21. SILLER-MATULA Gleichzeitige Behandlung mit Clopidogrel und PPI Auswirkungen auf die klinische Prognose. Jatros 2010;4:48-49.
  22. Jilma B, SILLER-MATULA Behandlung kardiovaskulärer Erkrankungen mit derzeit verfügbaren oralen Plättchenhemmern (Acetylsalicylsäure, Clopidogrel, Prasugrel). Pharmainformation 2010;25:3-5.
  23. SILLER-MATULA Plättcheninhibitoren in der Prävention der KHK. Leading Opinions 2009;4:9-11.
  24. SILLER-MATULA Indikationen für Plättchen-Inhibitoren in der Primär- und Sekundärprävention. Wiener Medizinische Wochenschrift 2009;7:23-24.
  25. SILLER-MATULA Koronare Herzkrankheit: Plättcheninhibitoren in der Prävention der KHK. Jatros 2009;5:12-15.
  26. Höchtl T, Schrör K, SILLER-MATULA JM, Freynhofer M, Wojta J, Huber K. Prasugrel, ein neues Thienopyridin. Kardiololgie Journal 2009;16:5-6.
  27. Christ G, SILLER-MATULA J, Huber K. Antithrombotische Behandlung nach einer Koronarstent-Implantation. Universum Innere Medizin 2009;07:76-78.
  28. SILLER-MATULA JM, Jilma B. Aspirin – Resistenz. Universum Innere Medizin 2008;04:20-21.
  • Thomas J. Linnemeier Spirit of Interventional Cardiology Award, TCT 2021, Orlando, USA
  • Werner Klein Award für translationale kardiovaskuläre Forschung; Österreichische Kardiologische Gesellschaft, 2021
  • “100 Women in Interventional Cardiology” Preis für international führende interventionelle Kardiologinnen, Washington, USA, CRT 2020
  • “CLIMB Auszeichnung für interventionelle Kardiologinnen”, Women as One
  • Young Leadership Recognition Program für interventionelle Kardiologie, Washington, USA, CRT 2019
  • TEAM in AF, Leadership Promotion Program in Vorhofflimmern, 2015
  • Auszeichnung für die beste Habilitation, Verein zur Förderung von Wissenschaft und Forschung WFWF, 2014
  • Auszeichnung der Stadt Wien für exzellente wissenschaftliche Leistungen auf dem Gebiet der Humanmedizin, 2014
  • Karl Link Early Career Investigator Award in Thrombosis by the American Heart Association (Arteriosclerosis, Thrombosis, and Vascular Biology), Orlando, USA, 2013
  • Werner Klein Preis für die beste translationale  Arbeit von der Österreichischen Kardiologischen Gesellschaft; “ARC15105 Is a Potent Antagonist of Von Willebrand Factor Mediated Platelet Activation and Adhesion”, 2012
  • Best Poster Award, “Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study”, Eurothrombosis 2012
  • Auszeichnung “best clinical paper” Österreichische Kardiologische Gesellschaft; “Phenotyping versus Genotyping for Prediction of Clopidogrel Efficacy and Safety: the PEGASUS-PCI study”, 2012
  • Maria Schaumayer Preis für die Doktor Arbeit, 2011
  • Science Slam Champion, Vienna 2010
  • Travel Award by the Vienna Science and Technology Fund, Euro Science Open Forum, Turin, Italy 2010
  • Researcher of the Month, Medizinische Universität Wien, 2009
  • Auszeichnung “best clinical paper” Österreichische Kardiologische Gesellschaft; “Calcium-channel blockers reduce the antiplatelet effect of clopidogrel”, 2009
  • Best Poster Award; “Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel”, Conference of the Society of Thrombosis and Haemostasis, 2009
  • Travel Award by the British Council, Euro Science Open Forum, Barcelona 2008
  • Travel Award by the Austrian Research Association, Scientific Sessions of the American Heart Association, New Orleans, 2008
  • ESC Conference Travel Award, Munich 2008
  • Austrian Radio Award and Second Prize of Jury in FameLab, 2008
  • Leistungsstipendium, Medizinische Universität Wien, 2004
  • Forschungsstipendium, Medizinische Universität Wien, 2004
  • Erasmus Stipendium, Medizinische Universität Wien, 2003
  • Leistungsstipendium, Medizinische Universität Warschau, 2003
  • Scapula Aurea Preis – Wettbewerb in Anatomie, 2001

Vorträge für Patienten:

  • „Herzgesundheit“ Vortrag in Rahmen der Fortbildungsreihe „Gesunde Gemeinde“, Zeiselmauer-Wolfpassing, 2023
  • “Geschlechtsspezifische Unterschiede in der Kardiologie ” MeinMed Vortragsserie für Patienten, Online Webinar, 2022;
  • “Auf den Spuren von Weidenrindenextrakt: was hat Aspirin mit Popstars zu tun?“, Vortrag in Rahmen von „Langen Nacht der Forschung“, Uni Wien, 2012;
  • “Primäre Prävention in Kardiologie”,  “Feel good day- Treffen für Haemophilie Patienten”, Wien, 2011;
  • “Medizinische Forschung an Menschen und Tieren:  Risiken, Ethik und Medien“, SciCom Konferenz, Wien, 2010
  • “Herzkrankheiten: sind Männer und Frauen gleich?”, Vortrag von NÖGKK, Gmünd, 2008;

Vorträge auf Einladung von ausländischen Universitäten:

  • Harvard Medical School – Massachusetts General Hospital Cardiology Grand Rounds, Boston, USA, 2022 „Advocating Cardiovascular Precision Medicine with use of antithrombotic drugs“;
  • University of Zurich and University of Bern, Switzerland, CAS Course in Sex- and Gender-Specific Medicine, Mai 2022 and July 2023, “Sex and Gender Differences in Platelet Function and Coagulation“;
  • Oregon Health Science University – Cardiology Grand Rounds Opening Lecture, USA, 2022 “Antithrombotic recipe for cardiogenic shock and out-of hospital cardiac arrest“;
  • Poznan University of Medical Sciences, Poland, 2017, Course in career development “How to read clinical articles in cardiology: translating data into clinical practice”;

Eingeladene Kongressvorträge:

  • “Precision medicine with antithrombotic agents for complex high risk PCI”, CRT Conference, Washington DC, USA, 2023
  • “Atrial Fibrillation: new aspects in anticoagulation”, Viennese Congress, Vienna, Austria, 2023
  • “Periprocedural antithrombotic treatment in women vs man”, Prevention and Intervention Conference, Warsaw, Poland, 2023
  • “What is new in Cardiology Guidelines after ESC 2023?”, Update in Cardiology, Hanusch Hospital, Vienna, Austria, 2023
  • “High Bleeding risk PCI: role of stent/balloon/scaffold design”, Meeting on Novel Technologies in Structural Heart & Coronary Interventions, Salzburg, Austria, 2023
  • “Meet the experts: reducing DAPT intensity after 1-3 months of acute coronary syndrome”, Annual Conference of the European Society of Cardiology, Amsterdam, 2023
  • “De-escalating Dual antiplatelet therapy after acute coronary syndome”, Annual Conference of the European Society of Cardiology, Amsterdam, 2023
  • “Implementation in real-world practice of ESC guidelines: NSTE-ACS clinical case”, Annual Conference of the European Society of Cardiology, Amsterdam, 2023
  • “Treating hypertensive patients with HFpEF: what is the role of beta-blockers?”, Annual Conference of the European Society of Cardiology, Amsterdam, 2023
  • “Short DAPT after CABG”, 16th International Cardiovascular Research Meeting in Bydgoszcz, Poland, 2023
  • “Atrial Fibrillation: Anticoagulation with NOACs”, 7th Conference of Cardiac Anesthesiology, Vienna, Austria 2023
  • “Urgent PCI in a STEMI patient without a cardiogenic shock”, EuroPCR, Paris, France 2023
  • “Emergencies in Cardiology”, Conference for Young Doctors, Billrothaus, Vienna, Austria, 2023
  • “Antithrombotic therapy for mechanical life support”, Annual Meeting of the Austrian Society of Cardiology, Salzburg, Austria, 2023
  • “Translational Highlights in Interventional Cardiology ”, Annual Meeting of the Austrian Society of Cardiology, Salzburg, Austria, 2023
  • “Preoperative Management of antithrombotic agents”, Morning Seminars in Anesthesiology, Vienna, Austria, 2023
  • “Diagnosis and treatment of patients with spontaneous coronary artery dissection” Seminars in Cardiology, Vienna, Austria, 2023
  • “Modern antithrombotic therapy for atrial fibrillation”, Update in Cardiology, Stockerau Hospital, Austria, 2023
  • “Precision medicine with use of antiplatelet agents”, Seminars in Clinical Pharmacology, Vienna, Austria, 2023;
  • “Discussant: Imaging and Physiology in Pre PCI Assessment”, Transcatheter Cardiovascular Technologies, TCT, Boston, USA, 2022
  • “Discussant: Gender and Racial disparities in PCI”, Transcatheter Cardiovascular Technologies, TCT, Boston, USA, 2022
  • “NOAKs for patients undergoing TAVI: studies and recommendations”, Seminars in Cardiology, Vienna, Austria, 2022
  • “Live case discussant: Hydra transcatheter valve implantation for severe aortic stenosis”, 23rd Conference of the Italian Society of Interventional Cardiology GISE, Milan, Italy 2022
  • “Calcium treatment: breaking the calcified ceiling”, XVIII Conference of the European Bifurcation Club, Madrid, Spain 2022
  • “Update of clinically relevant studies in cardiovascular emergency medicine” Department of Emergency Medicine, Clinic Ottakring, Vienna, Austria 2022
  • “Assessing the bleeding risk in women undergoing PCI: the role of invasive imaging”, Women Heart Programs NovaK Conference by the Serbian Society of Cardiology, Novi Sad, Serbia 2022
  • “CHIP + CTO PCI – are female patients undertreated?” Annual CHIP Meeting, Graz, Austria, 2022
  • “Efficacy and safety of Non-Vitamin K Antagonist in patients with valvular heart disease”, TAVI Expert Consensus Meeting, Vienna, Austria 2022
  • “Emergencies in Interventional Cardiology”, Conference for Young Doctors at Billrothhaus, Vienna, 2022
  • “Pharmacodynamics and kinetics of intravenous P2Y12 inhibitors in patients with cardiogenic shock– clinical implications”, XV International Cardiovascular Research Meeting ICVRM, Bydgoszcz, Poland, 2022
  • “Intravenous P2Y12 inhibitors: indication and long-term outcome”, Seminars in Cardiology, Hanusch Hospital, Vienna, Austria, 2022
  • “Spontaneous coronary artery dissection in a female patient – case report and discussion”, Meeting of the Working Group of Interventional Cardiology of the Austrian Society of Cardiology, Linz, Austria, 2022
  • “DAPT in CHIP PCI: Shall I shorten or lengthen my course?”, Calcium school of rock webinar, 2022
  • “Acute and chronic treatment of pulmonary embolism”, Seminars in Cardiology, Vienna, Austria, 2022
  • “Optimal antithrombotic therapy in cardiogenic shock due to acute coronary syndrome”, CRT Conference, Washington, USA, 2022
  • “ESC Update 2022: what is new in anticoagulant treatment of atrial fibrillation and valvular heart disease”, Webinar in Cardiology, 2022
  • Indications for left atrial appendage occlusion”; Annual Conference of the German Society of Cardiology (DGK), Mannheim, Germany, 2022
  • “Bifurcation Stenting: two stent strategy”, Coronary Academy, Vienna 2022
  • “Life case discussant: NSTE-ACS”, EuroPCR, Paris 2022
  • “Dual antiplatelet therapy for patients with high bleeding risk”, Advanced Therapies Summit, Istanbul, Turkey 2022
  • “How common is sub-clinical valve thrombosis in TAVI? Is it important?”, Advanced Therapies Summit, Istanbul, Turkey 2022
  • “DAPT: loading and duration” PCI crush curse, Graz, Austria 2022
  • “Coronary angiography projections and guiding catheters” PCI crush curse, Graz, Austria 2022
  • “OCT: how to and image interpretation” PCI crush curse, Graz, Austria 2022
  • “The future of research on antithrombotic and anticoagulant drugs”, the Annual Conference of the Austrian Society Cardiology, Salzburg, Austria 2022
  • “Anticoagulation and catheter – based therapies for acute pulmonary embolism”, the Annual Conference of the Austrian Society Cardiology, Salzburg, Austria 2022
  • “SGLT2 Inhibition in heart failure: mechanisms of action and clinical trials”, New Frontiers in treatment of heart failure, Grodzisk Mazowiecki, Poland, 2022  
  • “Antithrombotic drugs in cardiovascular indications”, Seminar for Nurses, Vienna, Austria 2022
  • “Antithrombotic strategies for PCI: guidelines versus clinical practice”, Cardiology Seminars, Mistelbach, Austria, 2022
  • „Optimal recipe for antiplatelet management in shock“, Society forCardiovascular Angiography and Interventions SCAI SHOCK Conference, USA, 2021
  • „Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement“, Medstar Washington Hospital Center Cardiac Cathlab Conference, USA, 2021
  • „Preventing recurrent stroke: which patient for drugs and which patient for left atrial appendage occlusion”; Annual Conference of the European Society of Cardiology (ESC), 2021
  • “Antithrombotic therapy in contemporary PCI: flowing through contemporary guidelines and clinical practice”, EuroPCR 2021
  • “Evolving paradigms in antithrombotic strategies for patients with cardiac diseases”, Cardiology Science Lunch at Charite, Berlin, Germany, 2021
  • “Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention”, XIV International Cardiovascular Research Meeting (ICVRM), Bydgoszcz, Poland 2021
  • “Complex patient with a cardiovascular disease: case presentation and discussion”, MEDCON; Vienna, Austria 2021
  • “Does a coronary stent choice play a role in patients at high bleeding risk?”, Webinar: Difficult questions in interventional cardiology, 2021
  • “Antithrombotic strategies for patients undergoing left atrial appendage occlusion”, Seminars in Cardiology, Vienna, Austria, 2021
  • “Polypharmacy in multimorbid cardiac patients: interdisciplinary challenges”; Pharmacy Update Webinar, 2021
  • “Challenging PCI cases in patients with highly calcified coronary arteries”, CLIMB educational lecture, 2021
  • “Intravenous antithrombotic drugs: indications and proper combination in high risk PCI”, grand rounds lecture, Hanusch Hospital, Vienna, 2021
  • “Dual antiplatelet therapy for patients with high bleeding risk”, Seminars in Cardiology, Vienna, Austria 2021
  • “What matters in double kiss crush technique for coronary bifurcations“, CRT Conference, Washington DC, USA, 2020
  • “Atrial fibrillation and acute coronary syndrome: translation into clinical practice”; Conference of the Austrian Society of Cardiology, 2020
  • “Controversies Regarding Subclinical Leaflet Thrombosis After TAVR”, Webinar by Radcliffe Cardiology, 2020
  • “Empagliflozin for heart failure with reduced ejection fraction”, Webinar: SGLT Inhibition for CV indications, 2020
  • “Cardiovascular risk with NSARs”, Webinar: Strategies to improve safety in patients treated with NSARs, 2020
  • “Aspirin use for primary prevention: still an option?”, Webinar: IX Conference: Frontiers in Antithrombotic Therapies, 2020
  • “Cangrelor: differences to standard of care”, Webinar: Strategies to improve outcome for high risk PCI, 2020
  • „Empagliflozin and dapagliflozin in patients hospitalized for acute decompensated heart failure“, International Cardiovascular Research Meeting (ICVRM), Bydgoszcz, Poland 2020
  • “Clinical relevance of Subclinical Leaflet Thrombosis After TAVR and SAVR”, Webinars in Interventional Cardiology, 2020
  • “All you need to know about high-bleeding risk patients undergoing PCI”, CardioReport Webinar, 2020
  • „The role of proximal optimisation (POT) in stenting of coronary bifurcations“, Seminars in Cardiology, Vienna, Austria, 2020
  • „Perioperative management of patients with atrial fibrillation and PCI treated with NOACs“, interdisciplinary expert webinar meeting, Austria, 2020
  • “Cangrelor as a first line P2Y12 Inhibitor for PCI in cardiac arrest”; Seminars in Cardiology, Floridsdorf Hospital, Vienna, Austria, 2019”
  • “Cardiovascular risk factors and COVID-19”, live webinar, Vienna, Austria, 2020
  • “How many actions and cardioprotective effects have NOACs”, 1st Myocardial Function Symposium „Targets in cardiometabolic disease“, Graz, Austria, 2020
  • “LANDI-UP: trial on landiolol utilization patters”, online webinar, Austria, 2020
  • “Cangrelor: past, present and future”, Cardiology Symposium, Vienna, Austria, 2019
  • “Pleiotropic effects of NOACs”, The Annual Meeting of the Austrian Cardiac Society, Salzburg, Austria, 2019
  • “Antithrombotics in PCI – short and safe, which combination and for how long”, Monthly Seminars in Cardiology, University Department of Cardiology, Krems, Austria, 2019
  • “Can we drop aspirin in acute coronary syndrome?”, 1st Viennese Congress in Cardiology, Vienna, Austria, 2019
  • “Highlights of the European Cardiology Conference 2019: clinically important trials”, Seminars in Cardiology, Hanusch Hospital, Vienna, Austria 2019
  • “Antithrombotics in Acute Coronary Syndrome: what is novel in ESC guidelines”, ESC wrap-up Conference, Vienna, Austria 2019
  • “Cangrelor as a therapy of choice in acute coronary syndrome: when and why”, ACS Strategy Symposium, Vienna, Austria, 2019
  • “CT Imaging for transcatheter aortic valve interventions”, Seminars in Radiology, Vienna, 2019
  • “Acute Coronary Syndrome and anticoagulation”, CEMIC Symposium in critical cardiac care, Vienna, Austria, 2019
  • “Challenges & considerations in Left Main Stenting”, Seminars in Cardiology, Vienna, Austria 2019
  • “Thrombo-Cardiology: triggers, targets, therapy” Coagulation Academy, Vienna, Austria 2019
  • “Triple therapy: end of the story for AF and PCI?”, Conference: Current issues in Cardiology, Vienna, Austria, 2019”
  • “The patient with cardiovascular risk factors”, Monthly Seminars in Cardiology, University Department of Cardiology, Sankt Pölten, Austria, 2019
  • “Antithrombotic treatment for a neurological patient with cardiovascular risk factors: challenges & considerations”, Neurology Meeting, Kaiser Franz Josef Hospital, Vienna, Austria 2019
  • “Triple antiplatelet therapy in atrial fibrillation and PCI”, Cardiology Seminars, Cardiovascular Rehabilitation Center, Groß Gerungs, Austria 2019
  • “NOAKs for a patient with a high risk of cardiovascular events: bleeding vs thrombosis”, Seminars in Internal Medicine, Hospital Barmherzige Brüder, Vienna, Austria, 2019
  • “Anticoagulant treatment for arterial and venous thrombosis in cardiovascular patients”, Seminars in Angiology, Medical University of Vienna, Vienna, Austria 2019
  • “Antithrombotic treatment in patients with cardiovascular diseases”, Seminars in Endocrinology, Wilhelminenhospital, Vienna, Austria 2019
  • “Transcatheter aortic valve replacement – case presentation”, C3 Heart Team Meeting, Vienna, Austria 2019
  • “Subclinical valve thrombosis: diagnosis and management”, Seminars in Cardiology, Vienna, Austria 2019
  • “Triple vs Dual antiplatelet therapy after PCI”, Cardiology Seminars, Hanusch Hospital, Vienna, Austria 2019
  • “Clinical implications of drug-drug interaction between P2Y12 receptor inhibitors and morphine”, Eurothrombosis, Barcelona, Spain 2018
  • “Individualized” antiplatelet therapy according to the pharmacology of P2Y12 inhibitors”, Conference on antiplatelet therapies by Polish Society of Cardiology, Warsaw, Poland 2018
  • “Is there a role for platelet function testing in the management of arterial disease?”, Annual Meeting of the Society of Thrombosis and Haemostasis Research (GTH), Vienna, Austria 2018
  • “NOACs in patients with cardiovascular risk profile”, Annual Cardiology Meeting, St. Pölten, Austria 2018
  • “Triple antithrombotic Therapy”, Seminars in Cardiology, Krems, Austria 2018
  • “Reactive versus efficient cardiovascular care with use of antiplatelet agents”, International Cardiovascular Research Meeting, Bydgoszcz, Poland 2018
  • “Switching strategies for P2Y12 receptor inhibitors – practical considerations”, Seminars in Cardiology, Vienna, Austria 2018
  • „Stent, Platelet function inhibitor, and Anticoagulation: triple, dual and mono-therapy”, Coagulation Academy, Vienna, Austria 2018
  • “Antithrombotic Therapies in cardiac indications: switching, pretreatment, therapy duration”, Seminars in Cardiac Catheterization, Vienna, Austria 2018
  • “Principles of antithrombotic therapies: cases”, Cardiology Prologue Symposium, Vienna, Austria 2018
  • “Intravascular ultrasound (IVUS) for PCI”, Seminars in Cardiac Catheterization, Vienna, Austria 2018
  • “Role for platelet function testing in the management of arterial disease?”, 3rd Thrombosis Meeting, Freiburg, Germany 2018
  • “Heart failure subtype and thromboembolic risk in patients with atrial fibrillation”, TEAM in Atrial Fibrillation Meeting, Windsor, UK, 2017
  • “Platelet function inhibitors: indications, characteristics, monitoring”, Intensive course in Haemosteseology, Vienna, Austria, 2017
  • “Ticagrelor – associated mortality reduction”, Annual Conference of the Polish Society of Cardiology, Katowice, Poland 2017
  • “Antithrombotics in cardiac indications: therapy duration, switching, pretreatment, triple therapy”, Seminars in Cardiology, Vienna, Austria 2017
  • “Optimal antiplatelet therapy in NSTEMI patients?” Autumn cardiology meeting, Poznan, Poland 2017
  • “Antiplatelet Therapy in acute and chronic phase of ACS treatment”, Seminars in Cardiology, Warsaw, Poland 2017
  • “Switching strategies for P2Y12 receptor inhibitors – practical considerations”, 10th International Cardiovascular Research Meeting, Bydgoszcz, Poland, 2017
  • “Antiplatelet treatment strategies in the acute phase of myocardial infarction”, Annual Scientific Meeting of the HCP Hospital, Poznan, Poland 2017 
  • “Controversy in treatment with antithrombotic agents”, Scientific Meeting of the Poznan Section of the Polish Society of Cardiology, Poznan, Poland, 2017
  • “Dual antiplatelet therapy and mortality reduction”, Scientific Meeting of the Cracow Section of the Polish Society of Cardiology, Cracow, Poland, 2017
  • “Antiplatelet treatment in the prehospital phase for an acute coronary syndrome”, Meeting for the emergency medical teams, Poznan, Poland, 2017
  • “Platelet reactivity testing – is there a clinical relevance?”, 21st Congress of the European Haematology Association, Copenhagen, Denmark, 2016
  • “Controversy of antiplatelet therapies?” Autumn cardiology meeting, Poznan, Poland 2016
  • “Platelet inhibitors: indications, characteristics, platelet function testing”, Intensive course in haemosteseology, Vienna, Austria, 2016
  • „Cangrelor – Replacement for the GPIIb/IIIa Inhibitors?“, Cardiology Live Conference, Vienna, Austria, 2016
  • “NSTE-ACS: which antiplatelet drug for whom?”, Conference of the Austrian Cardiac Society, Salzburg, Austria, 2016
  • Genetic profiling for patients under dual antiplatelet therapy: does it make sense?” Conference of the European Society of Cardiology, London, UK, 2015
  • “When do we need platelet function testing”, Intensive course in haemosteseology, Vienna, Austria, 2015
  • “Pre-treatment with P2Y12 receptors inhibitors in ACS”, Seminars in emergency medicine, Vienna, Austria, 2015
  • “Optimal duration of antiplatelet therapy”, Seminars for cardiologists of tomorrow, Salzburg, Austria, 2015
  • “Assessment of clinical efficacy of antiplatelet agents in patients with acute coronary syndrome”, 59th Annual Meeting of the Society of Thrombosis and Haemostasis Research, Düsseldorf, Germany 2015
  • “Pheno- and genotyping for prediction of antiplatelet drug safety and efficacy”, Annual Conference of the Society of Cardiology, Patras, Greece, 2015
  • “6-month antiplatelet treatment is sufficient-contra”, Conference of the Austrian Cardiac Society, Salzburg, Austria, 2015
  • “Pre-treatment with antiplatelet agents in NSTEMI-contra”, Cardiology Meeting, Vienna, Austria, 2015
  • “Monitoring of antiplatelet agents”, 1st Annual Congress of the European Society of Vascular Medicine, Potsdam, Germany, 2015
  • Platelet function testing and genetic profiling – Update 2014” Seminars in Cardiology, Vienna, Austria, 2014
  • “Cardiac health for haemophilia patients”, Annual Meeting of the Society of Haemophilia, Salzburg, Austria 2014
  • “Indications for platelet function testing”, Course in Haemostaseology, Vienna, Austria, 2014
  • “Acute coronary syndrome: new aspects regarding antiplatelet therapy”, Conference of Emergency Medicine, Vienna, Austria 2014
  • “How to improve the concept of individualized antiplatelet therapy – is an algorithm the answer?” Conference on coronary syndromes – questions and answers, Bydgoszcz, Poland 2014
  • “Individualized Therapy – are guidelines written for the patients or for the diseases”, Conference of the Austrian Cardiac Society, Salzburg, Austria, 2014
  • “Management of patients with an ACS treated with a direct oral anticoagulant – what does the guidelines say?”, Conference of the Austrian Cardiac Society, Salzburg, Austria, 2014
  • “Why have studies of personalized antiplatelet therapy failed so far?”, 11th InterCEPT, Milan, Italy, 2014
  • “Platelet Function Testing and Genetic Profiling in Clinical Practice: Status Quo”, 58th Annual Meeting of the Society of Thrombosis and Haemostasis Research, Vienna, Austria 2014
  • “Anticoagulation and physical training”, Conference on Rehabilitation Medicine, Vienna, Austria 2013
  • “Platelet function testing”, Course in Haemostaseology, Vienna, Austria, 2013
  • “Platelet inhibition in patients with acute coronary syndromes”, Seminars in Emergency Medicine, Vienna, Austria 2013
  • “ESC 2013 – Update”, Seminars in Cardiology, Vienna, Austria 2013
  • “Non-ST-elevation myocardial infarction: pathophysiology, diagnosis and treatment”, ACS Meeting, Ruprecht an der Raab, Austria, 2013
  • “Patients treated with vitamin K antagonist presenting with an acute coronary syndrome: an indication for double or triple antithrombotic therapy?”, Conference of the Austrian Society of Cardiology, Salzburg, Austria, 2013
  • “Clinical pharmacology and clinical profile of novel platelet inhibitors with a special considerations in patients with diabetes mellitus”, Journal Club in Endocrinology, Vienna, Austria 2013   
  • “Pathophysiology of platelets in patients with diabetes mellitus”, 57th Annual Meeting of the Society of Thrombosis and Haemostasis Research, Munich, Germany, 2013
  • “For which indications remains clopidogrel as a first choice therapy?”, Cardiology Conference, Innsbruck, Austria, 2013   
  • “Triple antithrombotic therapy” Seminars in Cardiology, Vienna, Austria 2012
  • “Personalized antiplatelet therapy”, Meeting of the Working Group of Interventional Cardiology of the Austrian Society of Cardiology, Linz, Austria 2012
  • “Antithrombotic management of atrial fibrillation in PCI patients”, Conference of the International College of Angiology, Innsbruck, Austria, 2012
  • “Clinical pharmacology of novel P2Y12 inhibitors”, Conference of the GermanSociety forExperimental andClinical Pharmacologyand Toxicology, Dresden, Germany, 2012
  • “Balancing between bleeding and thrombotic events: therapeutic window for ADP inhibitors”, Conference: Advances in Antiplatelet Therapy, Torun, Poland
  • “Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study” Press conference of the European Society of Cardiology, Munich, Germany, 2012
  • “Pharmacology of novel platelet inhibitors: considerations for clinical practice“ Conference of the Austrian Cardiac Society, Salzburg, Austria, 2012
  • “Individualized Antiplatelet Therapy – Fact of Fiction?”, Forum in pharmacotherapy, Vienna, Austria 2012
  • “Novel platelet inhibitors: therapy start, antidote, bridging and interaction”, Conference in Cardiology, Innsbruck, Austria 2012
  • “Newplateletinhibitors in thetreatment of acutecoronary syndrome”, Seminars in Cardiology, Vienna, Austria 2012
  • “Proton pump inhibitors: good for the stomach, bad for the heart”, Conference of the Austrian Society of Internal Medicine, Innsbruck, Austria, 2011
  • “Relevant druginteractionswithplateletaggregationinhibitors”, Seminar in Cardiology, Wels, Austria 2011
  • “Multiple Electrode Aggregometry: scientific experiences”, Multiplate Round Table Meeting, Munich, Germany 2011
  • “Novel targets for platelet inhibition to prevent stent thrombosis”, CardioWind, Heigerloch, Germany, 2011
  • “Phenotyping versus genotyping for prediction of antiplatelet drug efficacy and safety”, Conference: Presence and future of antiplatelet therapy; Runowo Krajenskie, Poland, 2011
  • “Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel” Press conference of the European Society of Cardiology, Stockholm, Sweden, 2010
  • “Drug-drug interactions in clopidogrel treatment”, Masterclass Conference, Vienna, Austria, 2010
  • “Stent thrombosis: antiplatelet drug efficacy and role of platelet function testing” International Conference on Platelets and Acute Coronary Syndrome, Torun, Poland, 2010
  • “Indications for antiplatelet therapy: primary and secondary prevention”, Conference of the Austrian Cardiac Society, Salzburg, Austria, 2009
  • “Drug-drug interactions involving clopidogrel”, International Conference on Platelets and Atherothrombotic Plaque, Bydgoszcz, Poland, 2009
  • “Biological contaminations of swimming pools – health aspects”, International Conference in Biochemistry of Boleslaw Krzysztofik, Plock, Poland, 2002
  • Deutsch
  • Englisch
  • Polnisch
FDcmcwzXIAArY6a
icomet
crf
prof siller-matula
Panel Siller-Matula
Siller-Matula calcium